Cargando…
Protocol Biopsy After Kidney Transplant: Clinical Application and Efficacy to Detect Allograft Rejection
Background Kidney transplant rejection is a major cause of graft dysfunction and failure. In recent years, there has been increased interest in renal allograft protocol biopsies to allow earlier detection of acute or chronic graft dysfunction or rejection to improve long-term graft survival and redu...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983784/ https://www.ncbi.nlm.nih.gov/pubmed/36874304 http://dx.doi.org/10.7759/cureus.34505 |
_version_ | 1784900615568097280 |
---|---|
author | Moein, Mahmoudreza Papa, Sarah Ortiz, Noelle Saidi, Reza |
author_facet | Moein, Mahmoudreza Papa, Sarah Ortiz, Noelle Saidi, Reza |
author_sort | Moein, Mahmoudreza |
collection | PubMed |
description | Background Kidney transplant rejection is a major cause of graft dysfunction and failure. In recent years, there has been increased interest in renal allograft protocol biopsies to allow earlier detection of acute or chronic graft dysfunction or rejection to improve long-term graft survival and reduce graft failure. This study aimed to determine if renal allograft protocol biopsies performed within the first 12 months after transplantation help detect subclinical graft dysfunction or rejection. Methods We performed a retrospective analysis utilizing SUNY Upstate University Hospital data from January 2016 to March 2022 to assess transplant outcomes and biopsies. The study population was divided into two subgroups: non-protocol biopsies and protocol biopsies within the 12 months post-transplant. Results A total of 332 patients met our inclusion criteria and were included in the study. Patients were divided into two subgroups: 135 patients (40.6%) in the protocol biopsy group and 197 patients (59.4%) with non-protocol indication biopsies during the first year after the transplant. The overall number of rejection episodes reported was eight episodes (4.6%) in the protocol biopsy group and 56 episodes (18.3%) in the non-protocol indication biopsy group, which was significantly higher in the non-protocol biopsy group (P=0.001). Antibody-mediated rejection (ABMR) and T-cell-mediated rejection (TCMR) diagnoses were significantly higher in the non-protocol biopsy group (P=0.03 and P=0.03, respectively). We also mentioned a trend in terms of mixed antibody-mediated rejection and T-cell-mediated rejection diagnosis (P=0.07). One year after the rejection, the mean glomerular filtration rate (GFR) was 56.78 mL/min/1.73m(2) in the protocol biopsy group and 49.14 mL/min/1.73m(2) in the non-protocol indication biopsy group, and there was no significant difference anymore (P=0.11). The patient survival rate was not significantly higher in the protocol biopsy group compared to the non-protocol indication biopsy group (P=0.42). Conclusion This study suggests that performing protocol biopsies does not significantly benefit rejection rates, graft survival, or renal function within the first 12 months post-transplant. Given these results and the small but non-zero risk of complications associated with protocol biopsies, they should be reserved for those patients at high risk of rejection. It may be more feasible and beneficial to utilize less invasive tests, such as DSA and dd-cfDNA testing, for early diagnosis of a rejection episode. |
format | Online Article Text |
id | pubmed-9983784 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-99837842023-03-04 Protocol Biopsy After Kidney Transplant: Clinical Application and Efficacy to Detect Allograft Rejection Moein, Mahmoudreza Papa, Sarah Ortiz, Noelle Saidi, Reza Cureus Pathology Background Kidney transplant rejection is a major cause of graft dysfunction and failure. In recent years, there has been increased interest in renal allograft protocol biopsies to allow earlier detection of acute or chronic graft dysfunction or rejection to improve long-term graft survival and reduce graft failure. This study aimed to determine if renal allograft protocol biopsies performed within the first 12 months after transplantation help detect subclinical graft dysfunction or rejection. Methods We performed a retrospective analysis utilizing SUNY Upstate University Hospital data from January 2016 to March 2022 to assess transplant outcomes and biopsies. The study population was divided into two subgroups: non-protocol biopsies and protocol biopsies within the 12 months post-transplant. Results A total of 332 patients met our inclusion criteria and were included in the study. Patients were divided into two subgroups: 135 patients (40.6%) in the protocol biopsy group and 197 patients (59.4%) with non-protocol indication biopsies during the first year after the transplant. The overall number of rejection episodes reported was eight episodes (4.6%) in the protocol biopsy group and 56 episodes (18.3%) in the non-protocol indication biopsy group, which was significantly higher in the non-protocol biopsy group (P=0.001). Antibody-mediated rejection (ABMR) and T-cell-mediated rejection (TCMR) diagnoses were significantly higher in the non-protocol biopsy group (P=0.03 and P=0.03, respectively). We also mentioned a trend in terms of mixed antibody-mediated rejection and T-cell-mediated rejection diagnosis (P=0.07). One year after the rejection, the mean glomerular filtration rate (GFR) was 56.78 mL/min/1.73m(2) in the protocol biopsy group and 49.14 mL/min/1.73m(2) in the non-protocol indication biopsy group, and there was no significant difference anymore (P=0.11). The patient survival rate was not significantly higher in the protocol biopsy group compared to the non-protocol indication biopsy group (P=0.42). Conclusion This study suggests that performing protocol biopsies does not significantly benefit rejection rates, graft survival, or renal function within the first 12 months post-transplant. Given these results and the small but non-zero risk of complications associated with protocol biopsies, they should be reserved for those patients at high risk of rejection. It may be more feasible and beneficial to utilize less invasive tests, such as DSA and dd-cfDNA testing, for early diagnosis of a rejection episode. Cureus 2023-02-01 /pmc/articles/PMC9983784/ /pubmed/36874304 http://dx.doi.org/10.7759/cureus.34505 Text en Copyright © 2023, Moein et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Pathology Moein, Mahmoudreza Papa, Sarah Ortiz, Noelle Saidi, Reza Protocol Biopsy After Kidney Transplant: Clinical Application and Efficacy to Detect Allograft Rejection |
title | Protocol Biopsy After Kidney Transplant: Clinical Application and Efficacy to Detect Allograft Rejection |
title_full | Protocol Biopsy After Kidney Transplant: Clinical Application and Efficacy to Detect Allograft Rejection |
title_fullStr | Protocol Biopsy After Kidney Transplant: Clinical Application and Efficacy to Detect Allograft Rejection |
title_full_unstemmed | Protocol Biopsy After Kidney Transplant: Clinical Application and Efficacy to Detect Allograft Rejection |
title_short | Protocol Biopsy After Kidney Transplant: Clinical Application and Efficacy to Detect Allograft Rejection |
title_sort | protocol biopsy after kidney transplant: clinical application and efficacy to detect allograft rejection |
topic | Pathology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983784/ https://www.ncbi.nlm.nih.gov/pubmed/36874304 http://dx.doi.org/10.7759/cureus.34505 |
work_keys_str_mv | AT moeinmahmoudreza protocolbiopsyafterkidneytransplantclinicalapplicationandefficacytodetectallograftrejection AT papasarah protocolbiopsyafterkidneytransplantclinicalapplicationandefficacytodetectallograftrejection AT ortiznoelle protocolbiopsyafterkidneytransplantclinicalapplicationandefficacytodetectallograftrejection AT saidireza protocolbiopsyafterkidneytransplantclinicalapplicationandefficacytodetectallograftrejection |